Why Celgene Is Poised to Keep Popping

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Celgene (NASDAQ: CELG  ) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Celgene, and see what CAPS investors are saying about the stock right now.

Celgene facts

 

 

Headquarters (founded)

Summit, N.J. (1980)

Market Cap

$41.8 billion

Industry

Biotechnology

Trailing-12-Month Revenue

$5.5 billion

Management

Chairman/CEO Robert Hugin

CFO Jacqualyn Fouse

Return on Equity (average, past 3 years)

21.9%

Cash / Debt

$3.8 billion / $3.1 billion

Competitors

Johnson & Johnson (NYSE: JNJ  )

Pfizer (NYSE: PFE  )

Amgen (NASDAQ: AMGN  )

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 96% of the 1,594 members who have rated Celgene believe the stock will outperform the S&P 500 going forward.

Earlier this month, one of those Fools, EpikurFool, succinctly summed up the Celgene bull case for our community:

High expected earnings growth, extremely profitable, still attractive valuation. Core holding in health care business.

Of course, that short pitch doesn't even come close to telling the entire story for Celgene. You're in luck, though. The Fool's brand-new premium report on Celgene looks at all sides of one of the most compelling biotechnology companies in the world. You can grab your copy, which comes with free updates for 12 months.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 15, 2013, at 8:08 PM, biotech101invest wrote:

    Agree 100% - CELG is still cheap at .80 PEG vs AMGN & BIIB at 1.2 and 1.3. And on conservative 2016 numbers its 0.4 - so you get the best EPS growth in all of healthcare (and almost all S&P 500) for more than half off. Also Big Apremilast news coming Mar 2 at AAD - could add $1 billion to analyst ests if PASI scores are as good as company seems to be indicating with their $1.5 to $2.0 billion in 2017 apremilast ests - analysts still have to move up significantly once they see detaile data in 2 wks. and then the big MM-020 front line data that Citi said this week could add an AMAZING $3.31-$7.71 of INCREMENTAL EPS when front line MM sales peak in EU. This stock, despite its run, is VASTLY undervalued with many upside items (ests include generic Vidaza like they have for 2 yrs - still none in sight, ests include NO BUYBACKS - billions a yr will continue, ests include little for China,Mexico, Brazil, Russia, Turkey, South Korea Revlimid sales - approvals coming international sales very conservative, ests include only $500 million EU front line in 2017 - most see $3 billion+. This stock is vastly undervalued.

Add your comment.

DocumentId: 2259832, ~/Articles/ArticleHandler.aspx, 4/17/2014 3:06:18 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement